Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/69816
DC FieldValueLanguage
dc.contributor.authorRecio Cruz, Carlota Pilaren_US
dc.contributor.authorGuerra, Borjaen_US
dc.contributor.authorGuerra Rodríguez, Miguel Alfonsoen_US
dc.contributor.authorAranda Tavío, Haidee Magdalenaen_US
dc.contributor.authorMartín-Rodríguez, Patriciaen_US
dc.contributor.authorde Mirecki-Garrido, Mercedesen_US
dc.contributor.authorBrito-Casillas, Yerayen_US
dc.contributor.authorGarcía-Castellano, José M.en_US
dc.contributor.authorEstévez-Braun, Anaen_US
dc.contributor.authorFernández Pérez, Leandro Fcoen_US
dc.date.accessioned2020-02-05T12:50:20Z-
dc.date.available2020-02-05T12:50:20Z-
dc.date.issued2019en_US
dc.identifier.issn0950-9232en_US
dc.identifier.otherScopus-
dc.identifier.urihttp://hdl.handle.net/10553/69816-
dc.description.abstractThe signal transducer and activator of transcription (STAT) are transcription factors that work via JAK/STAT pathway regulating the expression of genes involved in cell survival, proliferation, differentiation, development, immune response, and, among other essential biological functions, hematopoiesis. JAK/STAT signaling is strictly regulated under normal physiological conditions. However, a large group of diverse diseases has been associated to an aberrant regulation of STAT factors. Erroneous modulation of the pathway leads to constitutive STAT activation, thereby driving proliferation, inflammation, and an uncontrolled immune response. Deregulated STAT5 activation has been found in the development of many hematopoietic tumors, including chronic and acute leukemias, polycythemia vera, and lymphoma. Mutations in the kinases that phosphorylate STAT5, and/or overexpression of the upstream receptor-associated tyrosine kinases have been suggested as the main drivers of constitutive STAT5 activation. Hyper-activated STAT5 leads to the aberrant expression of its target genes including antiapoptotic, proliferative, and pro-inflammatory genes, favouring tumorigenesis. In this review, we intent to discuss the biology of JAK/STAT pathway, with particular focus on STAT5 and its crucial role in the development and progression of hematologic malignancies. Furthermore, we provide a synopsis of potential therapeutic strategies based on STAT5 activity inhibition that may represent an excellent opportunity for drug development in oncohematology.en_US
dc.languageengen_US
dc.relationDesarrollo Preclínico de Nuevas Estructuras Bioactivas Moduladoras de Las Actividades Oncogénicas de Stat3/5 O de Los Receptores de Estrógenosen_US
dc.relation.ispartofOncogeneen_US
dc.sourceOncogene [ISSN 0950-9232], v. 38 (24), p. 4657-4668en_US
dc.subject320101 Oncologíaen_US
dc.subject3207 Patologíaen_US
dc.subject.otherChronic Myeloid-Leukemiaen_US
dc.subject.otherHodgkin Lymphomaen_US
dc.subject.otherJanus Kinasesen_US
dc.subject.otherStat Proteinsen_US
dc.subject.otherSelf-Renewalen_US
dc.subject.otherBcr-Ablen_US
dc.subject.otherCellsen_US
dc.subject.otherImatiniben_US
dc.subject.otherMutationen_US
dc.subject.otherPathwayen_US
dc.titleSignal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematologyen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1038/s41388-019-0752-3en_US
dc.identifier.scopus85061924422-
dc.identifier.isi000471160500001-
dc.contributor.authorscopusid55354079200-
dc.contributor.authorscopusid7006442271-
dc.contributor.authorscopusid57206720991-
dc.contributor.authorscopusid57206731335-
dc.contributor.authorscopusid36604772400-
dc.contributor.authorscopusid57206729085-
dc.contributor.authorscopusid56236021400-
dc.contributor.authorscopusid6602732739-
dc.contributor.authorscopusid6701825073-
dc.contributor.authorscopusid6506777525-
dc.description.lastpage4668en_US
dc.identifier.issue24-
dc.description.firstpage4657en_US
dc.relation.volume38en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.contributor.daisngid1999350-
dc.contributor.daisngid909211-
dc.contributor.daisngid29589749-
dc.contributor.daisngid13167518-
dc.contributor.daisngid3922169-
dc.contributor.daisngid4588303-
dc.contributor.daisngid3255019-
dc.contributor.daisngid2034496-
dc.contributor.daisngid425077-
dc.contributor.daisngid30259663-
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Recio, C-
dc.contributor.wosstandardWOS:Guerra, B-
dc.contributor.wosstandardWOS:Guerra-Rodriguez, M-
dc.contributor.wosstandardWOS:Aranda-Tavio, H-
dc.contributor.wosstandardWOS:Martin-Rodriguez, P-
dc.contributor.wosstandardWOS:de Mirecki-Garrido, M-
dc.contributor.wosstandardWOS:Brito-Casillas, Y-
dc.contributor.wosstandardWOS:Garcia-Castellano, JM-
dc.contributor.wosstandardWOS:Estevez-Braun, A-
dc.contributor.wosstandardWOS:Fernandez-Perez, L-
dc.date.coverdateJunio 2019en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr3,232
dc.description.jcr7,971
dc.description.sjrqQ1
dc.description.jcrqQ1
dc.description.scieSCIE
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.author.deptGIR IUIBS: Farmacología Molecular y Traslacional-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Clínicas-
crisitem.author.deptGIR IUIBS: Farmacología Molecular y Traslacional-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Clínicas-
crisitem.author.deptGIR IUIBS: Farmacología Molecular y Traslacional-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Morfología-
crisitem.author.deptGIR IUIBS: Diabetes y endocrinología aplicada-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptGIR IUIBS: Farmacología Molecular y Traslacional-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Clínicas-
crisitem.author.orcid0000-0002-8832-2826-
crisitem.author.orcid0000-0003-4355-5682-
crisitem.author.orcid0000-0002-0047-1131-
crisitem.author.orcid0000-0002-0559-9097-
crisitem.author.orcid0000-0002-2378-3242-
crisitem.author.orcid0000-0003-0488-6307-
crisitem.author.orcid0000-0002-0707-7444-
crisitem.author.orcid0000-0001-7802-465X-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameRecio Cruz, Carlota Pilar-
crisitem.author.fullNameGuerra Hernández, Carlos Borja-
crisitem.author.fullNameGuerra Rodríguez, Miguel Alfonso-
crisitem.author.fullNameAranda Tavío, Haidée Magdalena-
crisitem.author.fullNameMartín Rodríguez, Patricia-
crisitem.author.fullNameDe Mirecki Garrido, Mercedes-
crisitem.author.fullNameBrito Casillas, Yeray-
crisitem.author.fullNameFernández Pérez, Leandro Francisco-
crisitem.project.principalinvestigatorFernández Pérez, Leandro Francisco-
Appears in Collections:Artículos
Show simple item record

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.